Amarin Corporation Plc

Amarin Corp. Plc is a biopharmaceutical company, which focuses on the commercialization and development of therapeutics for cardiovascular health. Its product development program leverages its experience in lipid science and the potential therapeutic benefits of polyunsaturated fatty acids. It has developed and markets Vascepa capsules through wholesale. The company was founded by Geoffrey W. Guy on March 1, 1989 and is headquartered in Dublin, Ireland.

Earnings data Q1 2021

Earnings data Q2 2021

Earnings data Q3 2021

Earnings data Q4 2021

Earnings data Q1 2022

Earnings data Q2 2022

Earnings data Q3 2022

Earnings data Q4 2022

Earnings data Q1 2023

Earnings data Q2 2023

Earnings data Q3 2023

Earnings data Q4 2023

Earnings data Q1 2024

Earnings data Q2 2024

Earnings data Q3 2024

Earnings data Q4 2024

Amarin reports robust Q4 earnings, eyes global expansion opportunities

Amarin's Q4 2022 earnings call highlighted strong financial performance, successful global expansion efforts, and a focus on cash preservation and talent acquisition. The company's UK launch milestones and international progress position it well for future growth.

Amarin reports Q1 revenue growth amidst pricing challenges and opportunities

Amarin focuses on revenue growth and cost-saving initiatives to drive operational efficiency and profitability.
The company's strong cash position provides stability for future growth initiatives and strategic investments.
Challenges include pricing pressure from generics and the need to balance expenses with revenue growth.
Opportunities lie in expanding prescription growth, product portfolio, and exploring strategic partnerships.

Amarin Corporation Plc reports robust Q3 earnings and strategic growth plans

Amarin Corporation Plc's Q3 2023 earnings call showcased strong financial performance, operational decisions driving positive cash flow, and a focus on maximizing shareholder value. While challenges in the European market and uncertainties around stock price were noted, opportunities for growth in global markets and strategic initiatives offer potential for future success.

Amarin reports solid Q4 revenue growth and eyes global expansion

Amarin's Q4 2023 performance reflects revenue growth and ongoing investment in strategic initiatives.
The company's strong financial position and operational momentum in key markets position it well for future growth.
Challenges around market dynamics, expenses management, and competition require strategic focus for sustained success.

Amarin reports stable Q1 earnings, focuses on European growth opportunities

Amarin Corporation's Q1 2024 earnings call highlighted solid financial performance, successful IP defense in Europe, and positive clinical outcomes for its key products. While facing challenges in the U.S. market due to generic competition, the company maintains profitability and a strong cash position. Opportunities lie in shareholder value enhancement and continued growth in Europe.

Amarin reports stable revenue but faces generic competition challenges

Amarin's Q2 2024 performance reflects revenue decline in the U.S. due to generic competition but improved net income from expense reductions. The company's strengths lie in the success of Vascepa/VAZKEPA and maintaining market share. Challenges include adapting to changing market dynamics, while opportunities exist in global expansion and strategic initiatives.

Amarin reports Q3 revenue of $42.3M, focuses on global expansion

Amarin's Q3 2024 performance reflects a mixed financial outcome with total net revenue of $42.3M and a GAAP net loss of $25.1M, impacted by challenges in the U.S. generic market.
Despite facing pricing pressures and cost reduction efforts, the company maintains a stable cash position of $306M and remains focused on global expansion.
The strengths lie in the proven science and support for VASCEPA/VAZKEPA, with opportunities to address the unmet need in reducing cardiovascular disease globally.
Challenges include navigating market dynamics and maintaining profitability amidst pricing pressures, while upcoming events signal proactive engagement for long-term value creation.

Revenue

Cost of revenue

Gross profit

Operating expenses

SG&A

Other

Operating income

EBITDA

Net income

Earnings per share

Total assets

Current assets

Cash & equivalents

Receivables

Inventory

Non-current assets

Net PPE

Intangibles

Total liabilities

Current liabilities

Short term debt

Income tax payable

Non-current liabilities

Long-term debt

Total equity

Stockholders equity

Minority interest

Total liabilities & equity

Total debt

Net debt

Book value per share

Cash from operations

Funds from operations

Change in working capital

Cash from investing

Capital expenditure

Purchase/sale of investments

Purchase/sale of business

Other sources

Cash from financing

Change in stock

Change in debt

Cash dividends paid

Cash from other sources

Net change in cash

Free cash flow

Amarin Corp. Plc is a pharmaceutical company, which focuses on the commercialization and development of therapeutics for cardiovascular health. It focuses on the development and commercialization of Vascepa capsules. The company was founded by Geoffrey William Guy on March 1, 1989 and is headquartered in Dublin, Ireland.

NEW YORK--(BUSINESS WIRE)--WHY: Rosen Law Firm, a global investor rights law firm, announces the filing of a class action lawsuit on behalf of purchasers of the securities of Amarin Corporation plc (NASDAQ: AMRN) between December 5, 2018 and June 21, 2021, inclusive (the “Class Period”). A class action lawsuit has already been filed. If you wish to serve as lead plaintiff, you must move the Court no later than December 23, 2021. SO WHAT: If you purchased Amarin securities during the Class Perio

EQUITY ALERT: ROSEN, A TOP RANKED LAW FIRM, Encourages Amarin Corporation plc Investors with Losses in Excess of $100K to Secure Counsel Before Important Deadline in Securities Class Action – AMRN

LOS ANGELES--(BUSINESS WIRE)---- $AMRN #AMRN--SHAREHOLDER ACTION ALERT: The Schall Law Firm Reminds Investors of a Class Action Lawsuit Against Amarin Corporation, plc

SHAREHOLDER ACTION ALERT: The Schall Law Firm Reminds Investors of a Class Action Lawsuit Against Amarin Corporation, plc and Encourages Investors with Losses in Excess of $500,000 to Contact the Firm

NEW YORK, Oct. 26, 2021 /PRNewswire/ -- Attorney Advertising -- Bronstein, Gewirtz & Grossman, LLC notifies investors that a class action lawsuit has been filed against Amarin Corporation plc ("Amarin" or the "Company") (NASDAQ: AMRN) and certain of its officers, on behalf of shareholders who purchased or otherwise acquired Amarin between December 5, 2018 and June 21, 2021, inclusive (the "Class Period"). Such investors are encouraged to join this case by visiting the firm's site: www.bgandg.com/amrn.

AMRN Investor Alert: Bronstein, Gewirtz & Grossman, LLC Notifies Amarin Corporation plc Investors of Class Action and Lead Deadline: December 20, 2021

SAN DIEGO--(BUSINESS WIRE)-- #AMRNstock--The suit alleges defendants issued false statements concerning Amarin business and prospects, resulting in its stock trading at inflated prices.

AMRN ALERT: Amarin Corporation plc Investors With Substantial Losses Have Opportunity to Lead Class Action Lawsuit

Boston, Massachusetts--(Newsfile Corp. - October 25, 2021) - The Thornton Law Firm alerts investors who purchased Amarin Corporation plc securities (NASDAQ: AMRN) between December 5, 2018 and June 21, 2021 may seek to participate in the case as a Lead Plaintiff. Interested investors may contact the Thornton Law Firm's investor protection team by visiting www.tenlaw.com/cases/Amarin for more information. Investors may also email investors@tenlaw.com or call 617-531-3917. A class action lawsuit has been filed on...

AMARIN Investor Alert: Class Action Lawsuit Filed

LOS ANGELES--(BUSINESS WIRE)---- $AMRN #AMRN--AMARIN CLASS ACTION NOTICE: The Schall Law Firm Files Securities Fraud Lawsuit Against Amarin Corporation, plc

CORRECTING and REPLACING AMARIN CLASS ACTION NOTICE: The Schall Law Firm Files Securities Fraud Lawsuit Against Amarin Corporation, plc

NEW YORK--(BUSINESS WIRE)-- #Amarin--Bragar Eagel & Squire, P.C., a nationally recognized stockholder rights law firm, announces that a class action lawsuit has been filed against Amarin Corporation PLC (“Amarin” or the “Company”) (NASDAQ: AMRN) in the United States District Court for the District of New Jersey on behalf of all persons and entities who purchased or otherwise acquired Amarin securities between December 5, 2018 and June 21, 2021, both dates inclusive (the “Class Period”). Investors hav

AMARIN ALERT: Bragar Eagel & Squire, P.C. Announces That a Class Action Lawsuit Has Been Filed Against Amarin Corporation PLC and Encourages Investors to Contact the Firm

AMARIN CLASS ACTION NOTICE: The Schall Law Firm Files Securities Fraud Lawsuit Against Amarin Corporation, plc

Boston, Massachusetts--(Newsfile Corp. - October 22, 2021) - The Thornton Law Firm alerts investors that a class action lawsuit has been filed on behalf of investors of Amarin Corporation plc (NASDAQ: AMRN). The case is currently in the lead plaintiff stage. Investors who purchased AMRN securities between December 5, 2018 and June 21, 2021 may contact the Thornton Law Firm's investor protection team by visiting www.tenlaw.com/cases/Amarin for more information. Investors may also email investors@tenlaw.com...

AMRN Investor Alert: Class Action Lawsuit Filed

DUBLIN, Ireland and BRIDGEWATER, N.J., Oct. 20, 2021 (GLOBE NEWSWIRE) -- Amarin Corporation plc (NASDAQ:AMRN) today announced that the Company will host a conference call with members of Amarin's senior management team to discuss the Company's third quarter 2021 financial results on Wednesday, November 3, 2021, at 7:30 a.m. ET. The conference call will follow the anticipated release of the company's financial results earlier that day.

Amarin to Report Third Quarter 2021 Financial Results and Host Conference Call on November 3, 2021

Amarin (AMRN) might move higher on growing optimism about its earnings prospects, which is reflected by its upgrade to a Zacks Rank #1 (Strong Buy).

All You Need to Know About Amarin (AMRN) Rating Upgrade to Strong Buy

Medifast

MKS Instruments

When looking for top stocks, instead of traditional valuation measures, look at stocks trading well below their upside potential. The post 3 Top Stocks With Upsides Over 50%, According to Wall Street Analysts appeared first on InvestorPlace.

3 Top Stocks With Upsides Over 50%, According to Wall Street Analysts

Amarin Corporation plc (AMRN) Management Presents at Cantor Fitzgerald Global Healthcare 2021 Conference (Transcript)

Amarin's gross margin has been growing from year to year and by the end of Q2 2021 was around 79.2%, which is significantly higher than the average for the healthcare. Vascepa sales increased 15% in Q2 2021 compared to Q2 2020.

Amarin: Maximum Optimism

Enables Amarin to Drive Additional Demand, Improve Patient Access & Education and Secure Proper Fulfillment and Reimbursement Enables Amarin to Drive Additional Demand, Improve Patient Access & Education and Secure Proper Fulfillment and Reimbursement

Amarin Outlines New Go-to-Market Strategy to Accelerate VASCEPA® (Icosapent Ethyl) Growth in U.S.

Brings groundbreaking therapy to patients in Germany with residual cardiovascular risk and marks key milestone in corporate growth strategy Brings groundbreaking therapy to patients in Germany with residual cardiovascular risk and marks key milestone in corporate growth strategy

Amarin Announces First European Launch of VAZKEPA (icosapent ethyl) in Germany

DUBLIN, Ireland and BRIDGEWATER, N.J., Sept. 13, 2021 (GLOBE NEWSWIRE) -- Amarin Corporation plc (NASDAQ:AMRN) today announced that members of the senior leadership team will participate in two upcoming virtual investment conferences in September 2021.

Amarin to Participate in September Investment Conferences

Arcturus Therapeutics

Arena Pharmaceuticals

bluebird bio

Cassava Sciences Inc

Theravance Biopharma

Buying biotech stocks while they're down is rewarding once they post positive clinical results, setting the stage for a big rally. The post 7 Busted Biotech Stocks Due for a Rebound appeared first on InvestorPlace.

7 Busted Biotech Stocks Due for a Rebound

Intercept Pharma

Inovio Pharmaceuticals

Plug Power

Zogenix

If these high-water price targets come to fruition, investors will be all smiles.

5 Stocks With 195% to 467% Upside, According to Wall Street

Amarin Stock Looks Attractive Despite U.S. Litigations

VASCEPA/VAZKEPA found in prespecified and post hoc analyses to reduce first and total primary endpoints by 26% and 35%, respectively, in REDUCE-IT patients with prior Myocardial Infarction

Amarin Reports Overview of Latest Clinical Research Evaluating VASCEPA®/VAZKEPA (Icosapent Ethyl) and Eicosapentaenoic Acid (EPA) Presented at ESC Congress 2021, Organized by the European Society of Cardiology

Amarin Corporation plc (NASDAQ: AMRN) announced additional data on Vascepa/Vazkepa (icosapent ethyl) in patients with prior heart attack, known as myocardial infarction (MI), at risk for major adverse cardiovascular events. The data were presented at the European Society of Cardiology.

Amarin Stock Moves Higher As Vascepa Cuts Risk Of Heart Attacks

VASCEPA found in prespecified and post hoc analyses to reduce first and total primary endpoints by 26% and 35%, respectively, in patients with prior Myocardial Infarction

Amarin Reports Data from REDUCE-IT® Showing VASCEPA®/VAZKEPA (Icosapent Ethyl) Significantly Reduces Ischemic Events in Patients with Prior Heart Attacks Presented in Late Breaking Science Session at ESC Congress 2021, Organized by the European Society of

Amarin-Supported Research and Analyses from International Academic Collaborators to Be Featured in Seven Presentations Amarin-Supported Research and Analyses from International Academic Collaborators to Be Featured in Seven Presentations

Latest Clinical Research Evaluating VASCEPA®/VAZKEPA (Icosapent Ethyl) in Patients with Residual Cardiovascular Risk to be Presented at ESC Congress 2021, Organized by the European Society of Cardiology

Amarin's (AMRN) Vascepa sales benefit from increased demand in the United States during the second quarter. The drug retains majority market share in its segment amid rising generic competition.

News for Amarin Corporation Plc Stock (AMRN)